AIM: To clarify the influence of hypertension on lower urinary tract symptoms (LUTS) we examined the relationship between blood pressure, LUTS, and the effect of terazosin on LUTS in patients with benign prostatic hyperplasia (BPH). METHODS: The subjects were patients who had LUTS and BPH. They were treated with terazosin (1 mg, twice-a-day) for 12 weeks. Calculation of the International Prostate Symptom Score (IPSS), measurement of blood pressure, and uroflowmetry were performed before and after 12 weeks of therapy. Patients were divided into a normotensive (NT) group and a hypertensive (HT) group at the time of first examination. RESULTS: The IPSS for urinary frequency and nocturia in BPH-HT patients (n = 21; mean age, 71 years) were significantly higher than those in the BPH-NT patients (n = 21; mean age, 69 years) before the administration of terazosin. The total IPSS the BPH-HT patients was also significantly higher than that of the BPH-NT patients. There were no differences of uroflowmetric parameters between the two groups. After 12 weeks of therapy, systolic and diastolic blood pressure decreased in the BPH-HT patients, but not in the BPH-NT patients. However, the systolic pressure of the BPH-HT patients was still significantly higher than that of the BPH-NT patients. The score for each IPSS parameter decreased in both groups, but the difference of the score between the two groups increased. CONCLUSION: Hypertension may worsen LUTS and may decrease the improvement of symptoms by terazosin.
AIM: To clarify the influence of hypertension on lower urinary tract symptoms (LUTS) we examined the relationship between blood pressure, LUTS, and the effect of terazosin on LUTS in patients with benign prostatic hyperplasia (BPH). METHODS: The subjects were patients who had LUTS and BPH. They were treated with terazosin (1 mg, twice-a-day) for 12 weeks. Calculation of the International Prostate Symptom Score (IPSS), measurement of blood pressure, and uroflowmetry were performed before and after 12 weeks of therapy. Patients were divided into a normotensive (NT) group and a hypertensive (HT) group at the time of first examination. RESULTS: The IPSS for urinary frequency and nocturia in BPH-HTpatients (n = 21; mean age, 71 years) were significantly higher than those in the BPH-NTpatients (n = 21; mean age, 69 years) before the administration of terazosin. The total IPSS the BPH-HTpatients was also significantly higher than that of the BPH-NTpatients. There were no differences of uroflowmetric parameters between the two groups. After 12 weeks of therapy, systolic and diastolic blood pressure decreased in the BPH-HTpatients, but not in the BPH-NTpatients. However, the systolic pressure of the BPH-HTpatients was still significantly higher than that of the BPH-NTpatients. The score for each IPSS parameter decreased in both groups, but the difference of the score between the two groups increased. CONCLUSION:Hypertension may worsen LUTS and may decrease the improvement of symptoms by terazosin.
Authors: M Kirby; C Chapple; G Jackson; I Eardley; D Edwards; G Hackett; D Ralph; J Rees; M Speakman; J Spinks; K Wylie Journal: Int J Clin Pract Date: 2013-04-25 Impact factor: 2.503
Authors: Mélanie Guilhen; Christophe Hennequin; Idir Ouzaid; Ingrid Fumagalli; Valentine Martin; Sophie Guillerm; Pierre Mongiat-Artus; Vincent Ravery; François Desgrandchamps; Laurent Quéro Journal: Radiat Oncol Date: 2018-10-24 Impact factor: 3.481